查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1585795

腦腫瘤藥物市場：按治療類型、適應症、分銷管道分類 - 全球預測 2025-2030

Brain Cancer Drugs Market by Therapy Type (Chemotherapy, Immunotherapy, Targeted Therapy), Indication (Glioblastoma, Meningioma, Pituitary Tumors), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年腦腫瘤藥物市場價值為20.3億美元，預計到2024年將達到21.8億美元，複合年成長率為7.43%，到2030年預計將達到33.5億美元。

腦腫瘤治療市場的範圍包括腦腫瘤特異性治療藥物的市場開拓、生產和分銷。這些包括化療、標靶治療、免疫療法和支持性治療藥物，旨在治療各種類型的腦腫瘤，如膠質母細胞瘤、星狀細胞瘤和寡樹突膠質瘤。腦腫瘤發生率的增加推動了對此類藥物的需求，並且需要能夠跨越血腦障壁並提供改進的療效且副作用更少的創新治療方法。這些藥物主要用於醫院、診所和專門的癌症治療中心，最終用戶是醫療保健相關人員和需要客製化癌症治療計劃的患者。

主要市場統計
基準年[2023] 20.3億美元
預測年份 [2024] 21.8億美元
預測年份 [2030] 33.5億美元
複合年成長率（%） 7.43%

市場成長受到醫療技術進步、研究經費增加以及對癌症早期檢測意識提高等關鍵因素的影響。個人化醫療和次世代定序技術的出現為標靶治療的發展提供了重大機會和成長潛力。製藥公司和研究機構之間的合作正在為創新藥物發現和臨床試驗打開大門。利用這些機會的主要建議包括投資於腫瘤基因和分子分析的藥物研發，從而可以實現更精確的標靶和改善患者的治療結果。

然而，這個市場也面臨著高昂的開發和核准成本、嚴格的監管要求以及有效跨越血腦障壁的挑戰等限制。另一個主要挑戰是，有些腦腫瘤具有侵襲性、復發率高，通常對常規治療方法有抵抗力。需要創新的領域包括開發有效針對腫瘤脈管系統和微環境的藥物，以及奈米顆粒等新型輸送系統，以增強藥物向大腦的傳遞。市場的本質是高度動態和競爭的，需要相關人員不斷創新和適應，以滿足未滿足的需求並克服現有的市場限制。

市場動態：揭示快速發展的腦腫瘤藥物市場的關鍵市場洞察

供需的動態交互作用正在改變腦腫瘤藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 與久坐生活方式相關的腦腫瘤盛行率增加
    • 患有神經病變的老年人口迅速增加
    • 提高患者對治療效果的認知
  • 市場限制因素
    • 使用標靶治療抑制癌症生長
  • 市場機會
    • 政府和製藥公司積極致力於藥物研發
    • 使用奈米顆粒傳輸藥物等領域取得了強勁進展
  • 市場挑戰
    • 核准這些藥物的嚴格監管指南

波特五力：駕馭腦瘤藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對腦腫瘤藥物市場的影響

外部宏觀環境因素在塑造腦腫瘤藥物市場的表現動態中發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解腦腫瘤治療藥物市場的競爭狀況

對腦腫瘤藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣腦瘤治療市場供應商的績效評估

FPNV定位矩陣是評估腦腫瘤治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃腦腫瘤藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對腦腫瘤藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 久坐的生活方式導致腦腫瘤的發生率增加
      • 患有神經系統疾病的老年人口迅速增加
      • 提高患者對治療可用性的認知
    • 抑制因素
      • 使用標靶治療阻止癌症生長
    • 機會
      • 政府和製藥公司對藥物開發的有利方法
      • 使用奈米粒子傳輸藥物等領域的強勁發展
    • 任務
      • 核准這些藥物的嚴格監管指南
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依治療類型分類的腦腫瘤藥物市場

  • 化療
  • 免疫療法
  • 標靶治療

第7章依適應症分類的腦腫瘤治療藥物市場

  • 神經膠母細胞瘤
  • 腦膜瘤
  • 腦下垂體瘤

第8章腦腫瘤藥物市場：按分銷管道

  • 醫院藥房
  • 零售藥房

第9章美洲腦腫瘤藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區腦腫瘤藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲腦腫瘤藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Antisense Therapeutics Limited
  • Aravive, Inc.
  • AstraZeneca PLC
  • Bristol Myers Squibb Company
  • Dr. Reddy's Laboratories
  • Elevar Therapeutics, Inc.
  • F. Hoffmann-La Roche AG
  • Fujifilm Corporation
  • GE Healthcare
  • Hitachi, Ltd.
  • Johnson & Johnson Services Inc.
  • Koninklijke Philips NV
  • Leadiant Biosciences, Inc.
  • Mankind Pharma Pvt. Ltd.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-434CCDA05263

The Brain Cancer Drugs Market was valued at USD 2.03 billion in 2023, expected to reach USD 2.18 billion in 2024, and is projected to grow at a CAGR of 7.43%, to USD 3.35 billion by 2030.

The scope of the market for brain cancer drugs encompasses the development, production, and distribution of therapeutic agents specifically targeting brain tumors. These include chemotherapy, targeted therapies, immunotherapy, and supportive care drugs aimed at treating different types of brain cancers like glioblastomas, astrocytomas, and oligodendrogliomas. The necessity for such drugs is driven by the increasing incidence of brain cancer, which requires innovative treatments that can penetrate the blood-brain barrier and offer improved efficacy with fewer side effects. The application of these drugs is mainly in hospitals, clinics, and specialized cancer treatment centers, with end-users consisting of medical professionals and patients requiring tailored cancer treatment plans.

KEY MARKET STATISTICS
Base Year [2023] USD 2.03 billion
Estimated Year [2024] USD 2.18 billion
Forecast Year [2030] USD 3.35 billion
CAGR (%) 7.43%

Market growth is influenced by key factors such as advancements in medical technology, increased research funding, and rising awareness of early cancer detection. The emergence of personalized medicine and next-generation sequencing technologies provide significant opportunities for developing targeted therapies, offering growth potential. Currently, collaborations between pharmaceutical companies and research institutions are opening doors for innovative drug discovery and clinical trials. A major recommendation to capitalize on these opportunities includes investing in R&D for drugs focusing on the genetic and molecular profiling of tumors, which can enable more precise targeting and improved patient outcomes.

However, the market also faces limitations from high developmental and approval costs, stringent regulatory requirements, and challenges in effectively crossing the blood-brain barrier. Another significant challenge is the aggressive nature of some brain tumors, which often leads to high relapse rates and resistance to conventional therapies. Areas ripe for innovation include the development of drugs that can effectively target tumor vasculature and microenvironment, and novel delivery systems such as nanoparticles to enhance drug delivery to the brain. The market's nature is highly dynamic and competitive, necessitating continuous innovation and adaptation by stakeholders to meet unmet patient needs and overcome existing market constraints.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Brain Cancer Drugs Market

The Brain Cancer Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of brain cancer with sedentary lifestyles
    • Surge in geriatric population suffering from neurological disorders
    • Rising patient awareness on the availability of treatment
  • Market Restraints
    • Use of targeted therapies to block cancer growth
  • Market Opportunities
    • Favorable initiatives from government and pharmaceutical companies in the development of the drug
    • Robust development in areas such as use of nanoparticles to carry drugs
  • Market Challenges
    • Strict regulatory guidelines in the approval of these drugs

Porter's Five Forces: A Strategic Tool for Navigating the Brain Cancer Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Brain Cancer Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Brain Cancer Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Brain Cancer Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Brain Cancer Drugs Market

A detailed market share analysis in the Brain Cancer Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Brain Cancer Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Brain Cancer Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Brain Cancer Drugs Market

A strategic analysis of the Brain Cancer Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Brain Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include Antisense Therapeutics Limited, Aravive, Inc., AstraZeneca PLC, Bristol Myers Squibb Company, Dr. Reddy's Laboratories, Elevar Therapeutics, Inc., F. Hoffmann-La Roche AG, Fujifilm Corporation, GE Healthcare, Hitachi, Ltd., Johnson & Johnson Services Inc., Koninklijke Philips N.V., Leadiant Biosciences, Inc., Mankind Pharma Pvt. Ltd., Merck & Co., Inc., Novartis International AG, Pfizer, Inc., Siemens Healthineers AG, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Brain Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapy Type, market is studied across Chemotherapy, Immunotherapy, and Targeted Therapy.
  • Based on Indication, market is studied across Glioblastoma, Meningioma, and Pituitary Tumors.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy and Retail pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of brain cancer with sedentary lifestyles
      • 5.1.1.2. Surge in geriatric population suffering from neurological disorders
      • 5.1.1.3. Rising patient awareness on the availability of treatment
    • 5.1.2. Restraints
      • 5.1.2.1. Use of targeted therapies to block cancer growth
    • 5.1.3. Opportunities
      • 5.1.3.1. Favorable initiatives from government and pharmaceutical companies in the development of the drug
      • 5.1.3.2. Robust development in areas such as use of nanoparticles to carry drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Strict regulatory guidelines in the approval of these drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Brain Cancer Drugs Market, by Therapy Type

  • 6.1. Introduction
  • 6.2. Chemotherapy
  • 6.3. Immunotherapy
  • 6.4. Targeted Therapy

7. Brain Cancer Drugs Market, by Indication

  • 7.1. Introduction
  • 7.2. Glioblastoma
  • 7.3. Meningioma
  • 7.4. Pituitary Tumors

8. Brain Cancer Drugs Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Retail pharmacy

9. Americas Brain Cancer Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Brain Cancer Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Brain Cancer Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Antisense Therapeutics Limited
  • 2. Aravive, Inc.
  • 3. AstraZeneca PLC
  • 4. Bristol Myers Squibb Company
  • 5. Dr. Reddy's Laboratories
  • 6. Elevar Therapeutics, Inc.
  • 7. F. Hoffmann-La Roche AG
  • 8. Fujifilm Corporation
  • 9. GE Healthcare
  • 10. Hitachi, Ltd.
  • 11. Johnson & Johnson Services Inc.
  • 12. Koninklijke Philips N.V.
  • 13. Leadiant Biosciences, Inc.
  • 14. Mankind Pharma Pvt. Ltd.
  • 15. Merck & Co., Inc.
  • 16. Novartis International AG
  • 17. Pfizer, Inc.
  • 18. Siemens Healthineers AG
  • 19. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. BRAIN CANCER DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. BRAIN CANCER DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. BRAIN CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. BRAIN CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BRAIN CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BRAIN CANCER DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PITUITARY TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. BRAIN CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. BRAIN CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023